** Shares of Tenaya Therapeutics TNYA.O down 21.7% premarket to record low 74 cents on equity raise
** Heart disease gene therapy developer late Mon announced pricing 75 mln units at 70 cents for gross proceeds of $52.5 mln
** Offering price represents 26% discount to stock's last sale
** Each unit comprises one share plus 5-yr warrant exercisesable at 80 cents, and 15-month warrant immediately exerciseable to purchase one-half share
** California-based co, which has 79.2 mln shares outstanding, plans to use net offering proceeds to fund ongoing development of its clinical and early-stage candidates, particularly TN-201 and TN-401
** Co late Mon also suspended and terminated its $75 mln "at-the-market" equity sales program, in which it entered into with Leerink Partners in 2022
** Leerink and Piper Sandler are jt bookrunners for the current offering
** Through Mon close, shares down 34% YTD and have shed nearly 90% of their value over the past 12 months
** Tenaya went public in Jul 2021 IPO priced at $15
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.